Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(04): 483-489
DOI: 10.4103/ijmpo.ijmpo_98_16
Original Article

Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor‑2/neu Expression in Breast Cancer with Various Clinicopathologic Factors

Cherry Bansal
Department of Pathology, Era's Medical College, Lucknow, Uttar Pradesh, India
,
Aarti Sharma
Department of Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
Mukta Pujani
Department of Pathology, ESIC Medical College, Faridabad, Haryana, India
,
Meenu Pujani
Lab Medicine, Metro Heart Institute and Super Speciality Hospital, Faridabad, Haryana, India
,
Kiran Sharma
Department of Genetics, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
,
A Srivastava
Department of Pathology, Era's Medical College and Hospital, Lucknow, Uttar Pradesh, India
,
U Singh
Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

Background: A significant development in the breast carcinoma management is the correlation between the presence of hormone receptors in the tumor and response to hormonal therapy and chemotherapy. Human epidermal growth factor receptor-2/neu (Her-2/neu) overexpression also serves as a very useful parameter to predict response to herceptin. Aim of Study: The study was conducted to correlate immunohistochemical expression of markers such as estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu with various clinicopathologic parameters. Materials and Methods: The study included 509 cases of breast carcinoma over a period of 5 years (from May 2009 to May 2014). Immunohistochemistry (IHC) for ER, PR, and her-2/neu was performed. Results: ER positivity was observed in 42.8% (218/509) cases, PR positivity in 31.8% (194/509) cases whereas her-2 neu positivity was seen in 40.7% (203/509) cases. Triple marker (ER, PR, and Her-2/neu) negative cases were 23.6% (120/509) cases. ER and PR expression was found to have a statistically significant correlation with tumor grade. Statistically significant correlation was observed between tumor size and tumor grade and her-2/neu expression. Her-2/neu expression showed statistically significant association with tumor stage. As the tumor grade increased, the proportion of triple-negative cases went on increasing, which was statistically significant. Conclusion: IHC has an increasingly important prognostic role in determination of factors that affect clinicopathologic features. Nevertheless, the results of this large series showed different patterns of findings with respect to clinicopathologic features.

Keywords

Breast cancer - estrogen receptor - human epidermal growth factor receptor-2/neu - hormone receptors - progesterone receptor


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used forcommercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
  • 2 Rosai J, editor. Breast. In: Rosai and Ackerman's Surgical Pathology. 10th ed. New York: Elsevier; 2011. p. 1660-771.
  • 3 Ellis IO, Pinder SE, Lee AH. Tumors of the breast. In: Fletcher CD, editor. Diagnostic Histopathology of Tumors. 3rd ed. Philadelphia: Elsevier; 2007. p. 903-70.
  • 4 Ayadi L, Khabir A, Amouri H, Karray S, Dammak A, Guermazi M, et al. Correlation of HER-2 over-expression with clinico-pathological parameters in tunisian breast carcinoma. World J Surg Oncol 2008;6:112.
  • 5 Ahmed HG, Al-Adhraei MA, Al-Thobhani AK. Correlations of hormone receptors (ER and PR), Her2/neu and p53 expression in breast ductal carcinoma among Yemeni women. Open Cancer Immunol J 2011;4:1-9.
  • 6 Vasudha M, Bharti M, Prashant R. Correlation of hormone receptor & Her 2/neu expression in breast cancer: A study at tertiary care hospital in South Gujarat. Natl J Med Res 2012;2:295-8.
  • 7 Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6.
  • 8 Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011;12:625-9.
  • 9 Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. Erb 2 expression and its association with other biological parameter of breast cancer Indian women. Indian J Cancer 2010;47:8-15.
  • 10 Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K, et al. Immunohistochemical analysis of ER, PR, her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev 2009;10:773-8.
  • 11 Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. Estrogen receptor-negative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
  • 12 Honma N, Sakamoto G, Akiyama F, Esaki Y, Sawabe M, Arai T, et al. Breast carcinoma in women over the age of 85: Distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 2003;42:120-7.
  • 13 Adebamowo CA, Famooto A, Ogundiran TO, Aniagwu T, Nkwodimmah C, Akang EE, et al. Immunohistochemical and molecular subtypes of breast cancer in Nigeria. Breast Cancer Res Treat 2008;110:183-8.
  • 14 Lu X, Gu Y, Ding Y, Song W, Mao J, Tan J, et al. Correlation of ER, pgR, HER-2/neu, p53, and VEGF with clinical characteristics and prognosis in Chinese women with invasive breast cancer. Breast J 2008;14:308-10.
  • 15 Pinto AE, André S, Pereira T, Nóbrega S, Soares J. C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis. Ann Oncol 2001;12:525-33.
  • 16 Looi LM, Cheah PL. C-erbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast correlates to high histologic grade and loss of estrogen receptor protein. Malays J Pathol 1998;20:19-23.
  • 17 Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52.
  • 18 Bamberger AM, Milde-Langosch K, Schulte HM, Löning T. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: Correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 2000;54:32-7.
  • 19 Kilinç N, Yaldiz M. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: Correlations with histopathological parameters. Eur J Gynaecol Oncol 2004;25:606-10.
  • 20 Prati R, Apple SK, He J, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer. Breast J 2005;11:433-9.
  • 21 Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-6.
  • 22 Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008;9:553-6.
  • 23 Rosenthal SI, Depowski PL, Sheehan CE, Ross JS. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 2002;10:40-6.
  • 24 Oakley GJ 3rd, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, et al. HER-2 amplification in tubular carcinoma of the breast. Am J Clin Pathol 2006;126:55-8.
  • 25 Almasri NM, Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005;7:R598-604.
  • 26 Ratnatunga N, Liyanapathirana LV. Hormone receptor expression and her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J 2007;52:133-6.
  • 27 Rashed MM, Ragab NM, Galal MK. The association of HER2/neu over expression in relation to p53 nuclear accumulation, hormonal receptor status andcommon clinicopathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma. Eur J Gen Med 2007;4:73-9.
  • 28 Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11:278-80.
  • 29 Cho EY, Choi YL, Han JJ, Kim KM, Oh YL. Expression and amplification of her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridization. Pathol Int 2008;58:17-25.
  • 30 Moradi-Marjaneh M, Homaei-Shandiz F, Shamsian SA, Mashhadi EZ, Hedayati-Moghadam MR. Correlation of HER2/neu over-expression, p53 protein accumulation and steroid receptor status with tumor characteristics: An Iranian study of breast cancer patients. Iran J Public Health 2008;37:19-28.
  • 31 Al-Moundhri M, Nirmala V, Al-Mawaly K, Ganguly S, Burney I, Rizvi A, et al. Significance of p53, bcl-2, and HER-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003;9:226-31.
  • 32 Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, et al. P53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 2006;8:R48.
  • 33 Hussein MR, Srah A, Abdulwahed AR. Alteration of estrogen receptors, progesterone receptors and c-erB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int 2008;32:698-707.
  • 34 Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.